Ceres Nanosciences Opens Advanced Particle Manufacturing Plant in Northern Virginia to Expand Nanotrap® Particle Manufacturing Capacity for COVID-19 Testing
MANASSAS, Va. — February 17, 2021 — Ceres Nanosciences, a privately held company that makes innovative products to improve diagnostic testing, announced that it has completed the build-out of a new 12,000-square-foot Advanced Particle Manufacturing Plant in Innovation Park, Prince William County, Virginia.
The new facility will be capable of generating a supply of Ceres’ Nanotrap® Magnetic Virus Particles to enable more than 10 million COVID-19 tests per month, with room for added capacity in the future.
Nanotrap® Magnetic Virus Particles improve diagnostic testing for COVID-19 by eliminating the need for RNA extraction kits, reducing sample processing time, and improving the sensitivity of the downstream assays in point-of-care systems, high-throughput laboratory tests, and wastewater and pooled sample testing workflows. Nanotrap® Magnetic Virus Particles also improve diagnostic testing for influenza virus, RSV, and variants of SARS-CoV-2.
The new facility was constructed in under 4 months with funding support from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. The rapid construction of the site was made possible with the support of Prince William County. The site is part of Pruitt Corporation’s Discovery Court development, and Pruitt also served as the general contractor. Facility Logix provided construction management support.
“This new facility is a huge step up in capacity for Ceres, giving us the ability to rapidly respond and scale to current and future virus outbreaks and testing needs,” said Ross Dunlap, Ceres Nanosciences CEO.
“We are thrilled that our new manufacturing plant is also located within Innovation Park near our existing R&D facility,” said Ben Lepene, Ceres Nanosciences CTO. “This means that we can ensure a stable supply of Nanotrap® particles to our growing portfolio of customers while simultaneously maintaining our development efforts for new Nanotrap® products right down the street.”
This project is supported by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative and has been funded in whole or in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92020C00021.
About Ceres Nanosciences, Inc.
Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic and research products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health, the Defense Advanced Research Projects Agency, the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency, and the Commonwealth of Virginia. Learn more, including how Ceres is partnering with leading life science, bio-pharmaceutical, and diagnostic companies at www.ceresnano.com.
Ross M. Dunlap
Ceres Nanosciences, Inc
1.800.615.0418 ext. 202
Latest posts by BioBuzz Media (see all)
- Robust Investment in Greater Philadelphia Region’s Cell and Gene Therapy Sector Continued in the First Quarter of 2021 - April 8, 2021
- Novavax Plan Outlines Expansion of Gaithersburg Corporate Campus - April 6, 2021
- CARB-X is Funding Baltimore’s Novel Microdevices to Develop a Rapid and Portable Diagnostic for STDs Including Antibiotic-Resistant Infections - April 6, 2021
- Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma - April 6, 2021
- Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover - April 5, 2021